Please click on the links below to access the commissioning policies. The associated Equality Impact Assessments, if currently available, are accessible here.
The CCGs’ position on the implementation of policies affecting patient referral can be found here.
Central nervous system
Central nervous system - commissioning policies
Aripiprazole long-acting (depot) injection for schizophrenia Botulinum Toxin A for the management of blepharospasmPatients diagnosed with blepharospasm should be advised to check with the Driver and Vehicle Licensing Agency (DVLA) the requirements for notification and assessment with regard to continuing their licence to drive.
Botulinum Toxin A for the management of hemifacial spasm
Brivaracetam for the management of epilepsy
Capsaicin (Qutenza®) for the treatment of peripheral neuropathic pain
Guanfacine prolonged-release capsules (Intuniv®) for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents
Lisdexamfetamine for the management of attention deficit hyperactivity disorder (ADHD) in children and adolescents
Lurasidone for schizophrenia
Olanzapine long-acting (depot) injection for schizophrenia
Paliperidone long-acting (depot) injection for schizophrenia
Safinamide for mid-to-late stage fluctuating Parkinson’s disease
Sativex for treatment of spasticity in multiple sclerosis
Skin surface applied functional electrical stimulation for an orthotic effect to correct foot drop of central neurological origin
Sodium oxybate for narcolepsy with cataplexy
Please note: Some commissioning policies approved by the previous commissioning organisations have not been reviewed and updated yet. However they are still applicable for the local population and can be accessed here.